Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
Title |
Type | $ Amount | Activity | Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Contract | $231,030.00 | Clinical Trial | Steve Chung | COM Phx Neurology | NCGS Incorporated | 03/2020 | |
| (00007885) A Randomized, Double-Blind, Placebo-Controlled Study of 4-Hydroxytamoxifen Topic Gel Among Women with Mammograpically Dense Breast - (Fixed Price) | Contract | $78,600.00 | Clinical Trial | Pavani Chalasani | Cancer Center Division | University of Texas: MD Anderson Cancer Center | 03/2020 |
| 2020 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award | Grant | $5,000.00 | Research | Jasmine Smith | Pediatrics | American Society of Hematology | 07/2020 |
| 5-HT1F Receptor Mediated Mitochondrial Biogenesis for The Treatment of Spinal Cord Injury | Fellowship | $112,449.00 | Research Training | Epiphani Simmons | Pharmacology and Toxicology | National Institute of Neurological Disorders and Stroke | 08/2020 |
| A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 with Placebo and with Tofacitinib in Combination with Conventional Synthetic DMARDs.... | Contract | $314,050.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | IQVIA RDS Inc. | 03/2020 |
| A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American men | Grant | $666,360.00 | Research training | David Garcia | Health Promotion Sciences | National Institute on Minority Health and Health Disparities | 02/2020 |
| A Genetically Engineered Human Fetal Liver Niche as a Novel Platform for Biomanufacturing of Hematopoietic Stem Cells | Grant | $248,129.00 | Research | David Harris | UAHS Research | University of Pittsburgh | 07/2020 |
| A Mixed Method to Identify Causes of Kidney Cancer Surgical Disparities in Arizona | Grant | $388,482.00 | Research | Ken Batai | Surgery | National Cancer Institute | 06/2020 |
| A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome (ARDS.. | Contract | $168,927.92 | Clinical Trial | Marilyn Glassberg Csete | COM Phx Internal Medicine | Kinevant Sciences, Inc. | 08/2020 |
| A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients with Brain Contusion | Contract | $96,267.00 | Clinical Trial | Bellal Joseph | Surgery | Biogen Incorporated | 03/2020 |
| A Novel Approach to Help Women of Reproductive Age Quit Smoking | Grant | $100,000.00 | Research | Alicia Allen | Family and Community Medicine | Prevent Cancer Foundation | 04/2020 |
| A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | Contract | $91,617.50 | Clinical Trial | Pavani Chalasani | Cancer Center Division | Zeno Pharmaceuticals, Inc. | 01/2020 |
| A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the Treatment of Advanced Solid Tumors with MAPK Pathway Mutations | Contract | $643,931.75 | Clinical Trial | Hani Babiker | Cancer Center Division | Strategia Therapeutics | 06/2020 |
| A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors | Contract | $458,027.74 | Clinical Trial | Hani Babiker | Cancer Center Division | Parexel International Corporation | 01/2020 |
| A Phase 1/2 Study of ZN-c3 as a Single Agent in Combination with Talazoparib or Pembrolizumab in Patients with Solid Tumors | Contract | $138,409.52 | Clinical Trial | Pavani Chalasani | Cancer Center Division | K-Group Beta, Inc. | 03/2020 |
| A Phase 1b/2 Study of AST-008 Combined with Pembrolizumab or Cemiplimab in Patients with Advanced Solid Tumors | Contract | $157,802.00 | Clinical Trial | Montaser Shaheen | Cancer Center Division | Exicure, Inc. | 06/2020 |
| A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors | Contract | $682,977.50 | Clinical Trial | Edward Gelmann | Cancer Center Division | Pharmacyclics Incorporated | 04/2020 |
| A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-cell Lymphoma (PTCL) in Adults Age 60 and Above | Contract | $147,691.00 | Clinical Trial | Daniel Persky | Cancer Center Division | Seattle Genetics, Incorporated | 05/2020 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated... | Contract | $55,928.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | Cumberland Pharmaceuticals, Incorporated | 07/2020 |
| A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses.... | Contract | $273,767.50 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Janssen Research & Development, LLC | 01/2020 |
| A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-3 | Contract | $80,418.76 | Clinical Trial | Franz Rischard | Medicine | Complexa, Inc. | 01/2020 |
| A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. | Contract | $171,440.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Incyte Corporation | 05/2020 |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects | Contract | $79,672.00 | Clinical Trial | Ramachandra Sista | COM Phx Internal Medicine | Vertex Pharmaceuticals, Incorporated | 05/2020 |
| A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple... | Contract | $392,700.50 | Clinical Trial | Krisstina Gowin | Cancer Center Division | AbbVie Incorporated | 07/2020 |
| A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Infants Born to.... | Contract | $124,499.00 | Clinical Trial | Mohamed Ahmed | Pediatrics | Pfizer, Incorporated | 05/2020 |